Parenchymal consolidation (HP:0032177)
Consolidation refers to an exudate or other product of disease that replaces alveolar air, rendering the lung solid (as in infective pneumonia).
Synonyms: No synonyms found for this term.
Comment: In radiographs and CT scans, consolidation appears as a homogeneous increase in pulmonary parenchymal attenuation that obscures the margins of vessels and airway walls (See Figure 19 of PMID:18195376). An air bronchogram may be present. The attenuation characteristics of consolidated lung are only rarely helpful in differential diagnosis (eg, decreased attenuation in lipoid pneumonia and increased in amiodarone toxicity).
Pubmed References: PMID:18195376
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Thyroid hormone synthesis | 0.0006123 | 0.01960 | 68.21 | 504.62 |
| 2 | Maturity onset diabetes of the young | 0.01293 | 0.09247 | 88.73 | 385.85 |
| 3 | Thyroid cancer | 0.01835 | 0.09247 | 61.59 | 246.23 |
| 4 | Autoimmune thyroid disease | 0.02619 | 0.09247 | 42.60 | 155.17 |
| 5 | Inflammatory bowel disease | 0.03204 | 0.09247 | 34.59 | 119.03 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | thyroid gland development (GO:0030878) | 5.033e-9 | 9.161e-7 | 1713.00 | 32730.63 |
| 2 | positive regulation of cell-cell adhesion mediated by cadherin (GO:2000049) | 0.000008085 | 0.0001471 | 713.68 | 8368.26 |
| 3 | endocrine system development (GO:0035270) | 1.812e-7 | 0.00001099 | 407.53 | 6326.45 |
| 4 | negative regulation of epithelial to mesenchymal transition (GO:0010719) | 3.266e-7 | 0.00001486 | 329.08 | 4914.57 |
| 5 | metanephric distal tubule development (GO:0072235) | 0.002498 | 0.01247 | 555.17 | 3326.77 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | intronic transcription regulatory region sequence-specific DNA binding (GO:0001161) | 0.002498 | 0.009991 | 555.17 | 3326.77 |
| 2 | DEAD/H-box RNA helicase binding (GO:0017151) | 0.003495 | 0.01141 | 370.07 | 2093.27 |
| 3 | aryl hydrocarbon receptor binding (GO:0017162) | 0.003994 | 0.01141 | 317.19 | 1751.86 |
| 4 | transcription regulatory region nucleic acid binding (GO:0001067) | 3.081e-8 | 0.000001232 | 95.57 | 1652.93 |
| 5 | glucocorticoid receptor binding (GO:0035259) | 0.004492 | 0.01198 | 277.53 | 1500.17 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | alveolar lamellar body (GO:0097208) | 0.000003371 | 0.00004719 | 1249.13 | 15739.23 |
| 2 | multivesicular body lumen (GO:0097486) | 0.000004719 | 0.00004719 | 999.25 | 12254.80 |
| 3 | late endosome lumen (GO:0031906) | 0.000008085 | 0.00005390 | 713.68 | 8368.26 |
| 4 | lamellar body (GO:0042599) | 0.00001750 | 0.00008749 | 454.07 | 4973.59 |
| 5 | multivesicular body (GO:0005771) | 0.0002403 | 0.0009613 | 110.81 | 923.40 |
Hub genes predicted as biomarkers & predicted FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| NKX2-1 | – |
| NAPSA | – |
| PAX8 | – |
| KRT7 | – |
| TG | ACEBUTOLOL, AMINOGLETETHIMIDE |
| SMAD3 | – |
| NCOA1 | – |
| FOXA2 | – |
| FOXA1 | – |
| SFTPB | STREPTOZOCIN |
